Podium to Practice: ESMO® 2026 – Breast: GIM3 FATA trial
OR
Studies / Trials Discussed
544RO – Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Novartis.
Studies/trials discussed:
544RO – Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.